pharmaceuticals

Handshake

Endo Shuffles the Deck With New CEO Appointment

Shares of Endo International PLC (NASDAQ: ENDP) saw a handy gain in Friday’s session after the company announced a change in senior management. The company said that its board of directors ...
Read Full Story »
GettyImages_183162370

Tobira Therapeutics Skyrockets on Allergan Acquisition

Tobira Therapeutics Inc. (NASDAQ: TBRA) shares skyrocketed on Tuesday after Allergan PLC (NYSE: AGN) announced that it will acquire the company. Both boards of directors have unanimously approved the transaction ...
Read Full Story »
Test tubes

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

We have talked in detail about how the political rhetoric has weighed upon the biotech industry. Toss in some scrutiny of pricing over a widely used product, and you have ...
Read Full Story »
Woman doing eye test with optometrist

Why Aeri Pharma Won So Big on a Single Trial

Shares of Aeri Pharmaceuticals Inc. (NASDAQ: AERI) skyrocketed early Thursday after the company issued positive results on its intraocular pressure (IOP) treatment in patients with glaucoma. Keep in mind that this ...
Read Full Story »
blood cells

Agios Files for Secondary Offering

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering. The company intends to offer up to $150 million of its ...
Read Full Story »
M&A

Vitae Shares Jump Over 150% on Allergan Acquisition

Allergan PLC (NYSE: AGN) announced early on Wednesday that it would be acquiring Vitae Pharmaceuticals Inc. (NASDAQ: VTAE). The goal of this transaction is to bolster Allergan’s dermatology product pipeline, and ...
Read Full Story »
FDA_logo

Key FDA Decisions and Trial Results Coming in the Next 2 Months

U.S. Food and Drug Administration (FDA) rulings and the results from clinical trials have proven time and again that they can make or break companies. The biotech and pharmaceutical ...
Read Full Story »
clinical trials

Jefferies Issues Top Pharma and Biohealth Stocks to Buy

Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward. One key analyst issued a few of its top picks ...
Read Full Story »
Prescription drugs

Major Pharma Continues to See Significant Drop in Short Interest

The short interest data have been released for the August 31 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
M&A

Why Horizon Pharma Is Not Overpaying for Raptor Pharma

Shares of Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) made a sizable gain early on Monday, after the company was announced that Horizon Pharma PLC (NASDAQ: HZNP) would be acquiring it. Horizon is hoping ...
Read Full Story »
clinical trials

4 Key BioPharma Movers in the Past Week

A few biotech companies made impressive runs over the course of this past week. In the past 52 weeks, biotech and pharmaceutical stocks have been absolutely crushed. However the year ...
Read Full Story »
Prescription drugs

Why Lexicon Pharma Is Soaring

Shares of Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) saw a handy gain on Friday after late-stage results came out. The company announced that its pivotal inTandem1 Phase 3 clinical trial of sotagliflozin ...
Read Full Story »
puzzle

Evaluating a GW Pharma Merger, Maybe

GW Pharmaceuticals PLC (NASDAQ: GWPH) has been on a tear in recent trading. The culprit was not exactly that the U.S. Food and Drug Administration (FDA) would be lenient on its ...
Read Full Story »
FDA_logo

Key FDA Decisions and Trial Results Expected in October

Biotech and pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair to a great amount of ...
Read Full Story »
Female patient on gurney

Did Agios Just Speed Up Its Business Plan by 2 Years?

Celgene Corp. (NASDAQ: CELG) is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals Inc. (NASDAQ: AGIO) significantly higher. In a surprise move, Celgene is ...
Read Full Story »